Late hepatitis B reactivation following direct-acting antiviral-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.

Vionnet, J.; Pascual, M.; Testoni, B.; Combet, C.; Godat, S.; Vijgen, S.; Aubert, V.; Rubbia-Brandt, L.; Zoulim, F.; Moradpour, D.

doi:10.1002/hep.29528

Late hepatitis B reactivation following direct-acting antiviral-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.

Details

Request a copy

Serval ID

serval:BIB_DD329BAFA656

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

Late hepatitis B reactivation following direct-acting antiviral-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.

Journal

Hepatology

Author(s)

Vionnet J., Pascual M., Testoni B., Combet C., Godat S., Vijgen S., Aubert V., Rubbia-Brandt L., Zoulim F., Moradpour D.

ISSN

1527-3350 (Electronic)

ISSN-L

0270-9139

Publication state

Published

Issued date

16/09/2017

Peer-reviewed

Oui

Volume

Number

Pages

791-793

Language

english

Notes

Publication types: Journal Article

Abstract

Direct-acting antivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver transplantation (LT). Hepatitis B virus (HBV) reactivation has been reported in HBV-HCV-coinfected patients treated with DAAs. We report on a case of late HBV reactivation after DAA-based treatment of recurrent hepatitis C in an antibody against hepatitis B core antigen (anti-HBc)-positive LT recipient. (Hepatology 2017).

Keywords

HBV-HCV coinfection, direct-acting antiviral, liver transplantation, replication space, viral interference

OAI-PMH

oai:serval.unil.ch:BIB_DD329BAFA656

DOI

10.1002/hep.29528

Pubmed

28921620

Web of science

000422694900035

Create date

05/10/2017 9:40